Get started
Author

Elaine Ginn

Observed names: E. Ginn, Elain Ginn
ORCID: 0000-0002-1952-8660
Observed ORCID: 0000-0002-1952-8660
OpenAlex ID: A5031385661
Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies
2015 · Matthew T. Burger, Gisele Nishiguchi, et al. · Journal of Medicinal Chemistry · 89
Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73
2020 · Joel W. Beatty, Erick A. Lindsey, et al. · Journal of Medicinal Chemistry · 68
Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
2022 · Dana Piovesan, Joanne B.L. Tan, et al. · Molecular Cancer Therapeutics · 58
Discovery of Potent and Selective PI3Kγ Inhibitors
2020 · Samuel L. Drew, Rhiannon Thomas-Tran, et al. · Journal of Medicinal Chemistry · 46
PDF
Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors
2020 · Dillon H. Miles, Xuelei Yan, et al. · ACS Medicinal Chemistry Letters · 24
Design, Synthesis, and Structure–Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ)
2021 · Guillaume Mata, Dillon H. Miles, et al. · Journal of Medicinal Chemistry · 19
Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy
2025 · Dillon H. Miles, Manjunath Lamani, et al. · Journal of Medicinal Chemistry · 6
46P AB521, a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor, for the treatment of renal cell carcinoma
2022 · K.V. Lawson, K.E. Sivick Gauthier, et al. · Annals of Oncology · 6
Abstract 1206: Discovery and characterization of AB521, a novel, potent, and selective hypoxia-inducible factor (HIF)-2α inhibitor
2021 · Kenneth V. Lawson, Kelsey E. Sivick Gauthier, et al. · Cancer Research · 5
Abstract A012: Discovery and characterization of Casdatifan (AB521), a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor
2024 · Kenneth V. Lawson, Artur Mailyan, et al. · Molecular Cancer Therapeutics · 3
Abstract PR001: Discovery of Etrumadenant, a first-in-class dual A2a and A2b adenosine receptor antagonist for cancer immunotherapy
2024 · Ehesan U. Sharif, Dillon H. Miles, et al. · Molecular Cancer Therapeutics · 3
Abstract 3862: AB474, a potent orally bioavailable inhibitor of arginase, for the treatment of cancer
2019 · Sterling C. Eckard, Yu Chen, et al. · Experimental and Molecular Therapeutics · 3
Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2α
2026 · Artur K. Mailyan, Guillaume Mata, et al. · Journal of Medicinal Chemistry · 2
Abstract 3862: AB474, a potent orally bioavailable inhibitor of arginase, for the treatment of cancer
2019 · Sterling C. Eckard, Yu Chen, et al. · Cancer Research · 1
Abstract A157: Preclinical pharmacokinetic and pharmacodynamic characterization of AB680, a small-molecule CD73 inhibitor for cancer immunotherapy
2019 · Joanne B.L. Tan, Jie Chen, et al. · Cancer Immunology Research · 1
Metabolism and excretion of the adenosine A2A/A2B receptor inhibitor, [14C]- Etrumadenant, in humans
2025 · Yanlin Zhu, Pei-Yu Chen, et al. · Drug Metabolism and Pharmacokinetics
Population Pharmacokinetics of Quemliclustat, a Potent, Selective, and Reversible CD73 Inhibitor, in Patients with Cancer
2024 · Jordon Johnson, Ian Linsmeier, et al.
PDF
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
2023 · Dana Piovesan, Joanne B.L. Tan, et al.
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
2023 · Dana Piovesan, Joanne B.L. Tan, et al.
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
2023 · Dana Piovesan, Joanne B.L. Tan, et al.
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
2023 · Dana Piovesan, Joanne B.L. Tan, et al.
Supplementary Data from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
2023 · Dana Piovesan, Joanne B.L. Tan, et al.
Data from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
2023 · Dana Piovesan, Joanne B.L. Tan, et al.
Data from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
2023 · Dana Piovesan, Joanne B.L. Tan, et al.
Abstract P206: AB521 potently and selectively inhibits pro-tumorigenic gene transcription by Hypoxia-Inducible Factor (HIF)-2α in vitro and in vivo
2021 · Kelsey E. Sivick Gauthier, Dana Piovesan, et al. · Molecular Cancer Therapeutics
Works count: 28
Citation count: 334
H-index: 6
I10-index: 6
Year
Topic
Type